Loading...
Loading...
BFRI| Name | Value |
|---|---|
| Revenues | 8.6M |
| Cost of Revenue | 3.1M |
| Gross Profit | 5.5M |
| Operating Expense | 10.1M |
| Operating I/L | -4.5M |
| Other Income/Expense | 0.3M |
| Interest Income | 0.0M |
| Pretax | -4.2M |
| Income Tax Expense | -0.0M |
| Net Income/Loss | -4.2M |
Biofrontera Inc. is a biopharmaceutical company specializing in the commercialization of pharmaceutical products for dermatological conditions in the United States. Its flagship product, Ameluz, is a prescription drug used in combination with the RhodoLED lamp series for photodynamic therapy to treat actinic keratosis. Additionally, the company offers Xepi, a prescription cream for impetigo treatment. Biofrontera generates revenue through the sale of these prescription drugs and medical devices, catering to the needs of patients with dermatological conditions.
